Journals / Ege Pediatri Bülteni / 2005 / Cilt: 12 - Sayı: 3

Drug induced liver disease in children

Çocuklarda ilaca bağlı hepatotoksisite

Pages
203–212
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The present article provides an overview of the mechanisms involved in drug-induced liver disease, together with the risk factors and disease characteristics associated with drug-induced hepatotoxicity.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Biotransformation of drugs is one of the major functions of liver.
📊
Key Findings & Data:Hepatic drug metabolism develops early in organogenesis and continues in postnatal life through puberty.
💡
Conclusion & Impact:The present article provides an overview of the mechanisms involved in drug-induced liver disease, together with the risk factors and disease characteristics associated with drug-induced hepatotoxicity.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Biotransformation of drugs is one of the major functions of liver. Hepatic drug metabolism develops early in organogenesis and continues in postnatal life through puberty. Although drug-induced liver disease is less common in children, several reports of hepatotoxicity are published every year. Acquired and genetic factors influence the individual susceptibility to drug hepatotoxicity. The present article provides an overview of the mechanisms involved in drug-induced liver disease, together with the risk factors and disease characteristics associated with drug-induced hepatotoxicity.

Özet

İlaçların biyotransformasyonu karaciğerin en önemli fonksiyonlarından birisidir. Hepatik ilaç metabolizması organogenezisin erken döneminde başlamakta ve püberteye kadar devam etmektedir. Her nekadar ilacın indüklediği karaciğer hastalığı çocuklarda sık görülmese de her yıl hepatotoksisite ile ilgili birkaç rapor bildirilmektedir. Edinsel ve genetik faktörler ilaç hepatotoksisitesi için kişisel hassasiyeti etkilemektedir. Bu makalede ilacın indüklediği karaciğer hasarının mekanizması, risk faktörleri ve ilacın indüklediği hepatotoksisite ile ilişkili karakteristik hastalıklar sunulmaktadır.

🔖

Cite This Article

TÜMGÖR, G., YAĞCI, R. V., ARIKAN, Ç. (2022). Drug induced liver disease in children. Ege Pediatri Bülteni, Cilt: 12 - Sayı: 3, 203–212. https://ajindex.com/articles/495764

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Roberts EA. Drug-induced hepatotoxicity.In: Walker WA, Qoulet O, Kleinrnan RE, Sherman PM, Shneider BL, Sanderson IR (eds). Pediatric gastrointestinal disease (4th ed) Vol 2. Ontario: BC Decker, 2004: 1219-1240.
  2. Buratti S, Lavine JE. Drugs and the liver: advances in metabolism, toxicity, and therapeutics. Curr Opin Pediatr 2002; 14: 601-607. Zimmerman H. Drug-induced liver disease. In: Schiff E, Sorell M, Madding W (eds).Schiffs diseases of the liver (8th ed). Philadelphia: Lippencourt Raven, 1999: 973-1064. Kaplowitz N. Drug-induced liver injury. Clin Infect Dis 2004; 1: 44-48. Roberts EA. Drug-induced liver disease. In: Suchy FJ, Sokol RJ, Balistreri WF (eds). Liver Disease in Children (2nd ed). Philadelphia: Lippincot Williams & Wilkins, 2001: 463-İ91. Farrell GC. Liver disease caused by drugs, anesthetics and toxins. In: Feldman M, Friedman LS, Sleisenger MH (eds). Sleisenger & Fordtran's Gastrointestinal and Liver Disease (7th ed). Philadelphia: WB Saunders, 2002: 1403-1447.
  3. Clarkson A, Choonara I. Surveillance for fatal suspected adverse drug reactions in the UK. Arch Dis Child 2002; 87: 462-467.
  4. Pham TV, Lu S, Kaplowitz N. Acetaminophen hepatotoxicity. In: Taylor MB (ed). Gastrointestinal emergencies (2nd ed). Baltimore: Williams & Wilkins, 1997: 371-388. Kaplowitz n Mechanisms of cell death and relevance to drug hepatotoxicity. In: Kaplowitz N, DeLeve LD (eds). Drug-induced liver disease (1st ed). Mew York: Marcel Dekker, 2002: 85-95. Kaplowitz N. Biochemical and cellular mechanisms of toxic liver injury. Semin Liver Dis 2002; 22:137-144. Kaplowitz N. Mechanisms of liver cell injury. J Hepatol 2000; 32: 39-47. Kaplowitz N. Cell death at the millennium: implications for liver distress. Clin Liver Dis 2000; 4:1. DeLeve L, Wang X, Kuhlenkamp J, Kaplowitz N. Tpxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venooclusive disease. Hepatology 1996; 23:589-599.
  5. Odin JA, Huebert RC, Casciola-Rosen L, et al. Bcl-2dependant oxidation. J Clin Invest 2001; 108: 223-232.
  6. Beune PH, Lecoeur J. Immunotoxicity of the liver: adverse reactions to drugs. J Hepatol 1997; 26: 37-42.
  7. Robin MA, Le Roy M, Descatoire V, et al. Plasma membrane cytochrome P450 as neoantigens and autoimmune targets in drug-induced hepatitis. J Hepatol 1997; 26: 23-30.
  8. Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis 2002; 6: 467-486. Kitteringham MR. Drug-protein con